Protein Kinase Inhibitors: all 15,038 studies that test it

Page 78 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.

• Adjunctive Everolimus Treatment of Refractory EpilepsyStatus unknownNCT05613166Phase 2
• Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor SubjectsStatus unknownNCT05610202Phase 1
• Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1
• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Active, not recruitingNCT05607550Phase 3
• To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 WeeksStatus unknownNCT05606107Phase 4
• Low-dose Interleukin-2 and Rapamycin on sjögren's SyndromeCompletedNCT05605665Phase 1/2
• RP-6306 in Patients With Advanced CancerCompletedNCT05605509Phase 2
• Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCTWithdrawnNCT05604755Phase 2
• Zandelisib + Tazemetostat in R/R Follicular LymphomaWithdrawnNCT05604417Phase 1/2
• Anlotinib and Radiotherapy in Resectable Soft Tissue SarcomaStatus unknownNCT05602415Phase 2
• Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With DupilumabCompletedNCT05602207Phase 4
• Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingNCT05601973Phase 2
• Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT ModelCompletedNCT05600855Phase 2
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationCompletedNCT05593328Phase 2
• A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruitingNCT05593094Phase 1/2
• Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisActive, not recruitingNCT05588843Phase 2
• Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb StudyCompletedNCT05586841Phase 1
• Drug-drug Interaction Study of XZP-3621 TabletStatus unknownNCT05586568Phase 1
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloCompletedNCT05583526Phase 3
• Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerTerminatedNCT05583110Phase 2
• A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsCompletedNCT05579574Phase 1
• Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver TransplantationStatus unknownNCT05576909Phase 2
• Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2
• HMPL-523 Food Effect and Proton Pump Inhibitor StudyCompletedNCT05571787Phase 1
• Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic TherapyWithdrawnNCT05567406Phase 2
• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive, not recruitingNCT05567185Phase 1
• Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET AlterationsWithdrawnNCT05567055Phase 2
• DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Active, not recruitingNCT05566795Phase 3
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor CancerActive, not recruitingNCT05566574Phase 1/2
• Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/RearrangementsTerminatedNCT05565794Phase 2
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2
• Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Active, not recruitingNCT05564403Phase 2
• Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular CarcinomaWithdrawnNCT05564338Phase 3
• A Trial of DDI Between SHR1459 and Efavirenz With Healthy SubjectsCompletedNCT05560360Phase 1
• Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction PatientsStatus unknownNCT05559242Phase 1
• RMC-5552 Monotherapy in Adult Subjects With Recurrent GlioblastomaTerminatedNCT05557292Phase 1
• A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815Active, not recruitingNCT05557045Phase 1
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor ZapnometinibCompletedNCT05555823Phase 1
• TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Phase 2
• Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialActive, not recruitingNCT05554380Phase 2
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
• Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Phase 1
• Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Status unknownNCT05549284Phase 2
• Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy AdultsCompletedNCT05547399Phase 1
• Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingNCT05546866Phase 2
• A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentCompletedNCT05546151Phase 1
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2
• Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceStatus unknownNCT05545124Phase 2
• Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsActive, not recruitingNCT05544552Phase 1/2
• Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive, not recruitingNCT05538897Phase 1/2
• A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsCompletedNCT05538572Phase 1
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsActive, not recruitingNCT05538130Phase 1
• Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsStatus unknownNCT05537987Phase 1
• HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingNCT05535933Phase 2/3
• ABSK091 Food Effect Study in Healthy SubjectsCompletedNCT05533788Phase 1
• Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.Status unknownNCT05532072Early Phase 1
• Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.CompletedNCT05529667Phase 1/2
• Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult SubjectsCompletedNCT05528120Phase 1
• Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 InfectionActive, not recruitingNCT05527418Phase 2
• Ursodeoxycholic Acid in C. Difficile InfectionTerminatedNCT05526807Not applicable
• A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)Active, not recruitingNCT05526755Phase 2
• Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)TerminatedNCT05524857Phase 1
• Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)CompletedNCT05524311Phase 2
• A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisCompletedNCT05523765Phase 2
• Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
• A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaActive, not recruitingNCT05520567Phase 1/2
• PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic CancerTerminatedNCT05518110Phase 2
• Study of SHR6390 in Renal Insufficiency and Healthy SubjectsStatus unknownNCT05515289Phase 1
• Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC TrialWithdrawnNCT05514912Phase 2
• A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant CancerActive, not recruitingNCT05514496Phase 1
• A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingNCT05514132Phase 1
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With RemibrutinibActive, not recruitingNCT05513001Phase 3
• Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerStatus unknownNCT05512780Phase 2
• Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast CancerStatus unknownNCT05512416Phase 2
• Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisTerminatedNCT05511519Phase 2
• Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal CancerCompletedNCT05510895Phase 2
• Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
• Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated CytopeniasWithdrawnNCT05509582Phase 2
• Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingNCT05508906Phase 1
• A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid TumorsStatus unknownNCT05508620Phase 1
• Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2
• Single Dose Glumetinib in Healthy Chinese Male SubjectsCompletedNCT05507294Phase 1
• Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver DiseaseCompletedNCT05506488Phase 1/2
• Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2
• A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid TumorsTerminatedNCT05501912Phase 1
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingNCT05501886Phase 3
• Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by StatinStatus unknownNCT05500937Phase 2/3
• Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCActive, not recruitingNCT05498896Phase 2
• Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLStatus unknownNCT05498259Phase 2
• Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)CompletedNCT05497843Phase 2
• TQB3616 Capsules in the Treatment of Dedifferentiated LiposarcomaTerminatedNCT05496569Phase 2
• A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
• Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedNCT05494580Phase 1/2
• A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.CompletedNCT05493995Phase 2
• HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCCStatus unknownNCT05493332Phase 2
• Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
• Human Mass Balance and Biotransformation Study of [14C]AfuresertibCompletedNCT05489744Phase 1

← Protein Kinase Inhibitors overview